Connect your AI

SIGA Technologies SIGA Stock-Based Comp

Stock-Based Comp at other companies

Emergent BiosolutionsEBS

$1.9M+26.7%

Opko HealthOPK

$2.74M+4.5%

Merck & Co.MRK

$185M-5.1%

Stoke Therapeutics, Inc.STOK

$8.75M+29.6%

Septerna, Inc.SEPN

$6.02M+306%

Apogee Therapeutics, Inc.APGE

$17.16M+54.2%

Other financials

Income statement

Revenue$6.2M-11.3%

Gross profit$3.3M-52.0%

Operating income-$5.3M-136%

Net income-$3.5M-746%

EPS (diluted)-$0.05-400%

Balance sheet

Cash & equivalents$145.6M-10.3%

Total debt$601.0K-50.6%

Total equity$151.6M-29.8%

Total assets$219.4M-11.2%

Cash flow

Operating cash flow-$8.7M-223%

CapEx--100%

Free cash flow-$8.7M-223%

Valuation

Market cap$261.08M-44.3%

Enterprise value$116.11M-59.6%

P/E10.3×+3.8×

P/S2.8×+0.2×

Profitability

Gross margin65.4%-11.2pp

Operating margin52.4%-7.8pp

Net margin43.2%-6.1pp

FCF margin66.2%—

Returns & leverage

Return on equity39.9%-18.5pp

Debt / equity0×0.0×

Current ratio3.2×-5.2×

Where this comes from

Reported directly by SIGA Technologies in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: SIGA Technologies’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about SIGA Technologies's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is SIGA Technologies's stock-based comp?: SIGA Technologies (SIGA) reported stock-based comp of $752.97K in Q1 2026.
How has SIGA Technologies's stock-based comp changed year-over-year?: SIGA Technologies's stock-based comp decreased by 16.5% year-over-year, from $902.28K to $752.97K.
What is the long-term trend for SIGA Technologies's stock-based comp?: Over 4 years (2021 to 2025), SIGA Technologies's stock-based comp has grown at a 30.6% compound annual growth rate (CAGR), from $1.27M to $3.68M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.